Lipid Particle Nucleic Acid Delivery Cytotoxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid delivery methods face challenges such as high cytotoxicity of cationic lipid carriers, instability of nucleic acids in blood, and inefficient intracellular delivery, which hinder effective therapeutic outcomes.
Innovation Solution
A lipid particle composition comprising a phospholipid with amino groups and nitrogen-containing heterocyclic groups, a neutral lipid without nitrogen-containing heterocyclic groups, a sterol, and a nucleic acid, which forms a non-liposomal structure to reduce cytotoxicity and enhance intracellular uptake and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipid carriers are used to transfer nucleic acids into cells, then transfer efficiency is improved, but cytotoxicity increases
Solution Approach 1:
The patent changes the chemical parameters of the lipid carrier by introducing specific heterocyclic groups (imidazole, pyrimidine, purine) at defined positions in the lipid molecule. This structural parameter change enables the carrier to maintain cationic character for nucleic acid binding while reducing cytotoxicity through the specific chemical properties of the heterocyclic groups.
Solution Approach 2:
The patent creates a composite lipid structure combining conventional lipid components with specifically positioned heterocyclic groups. This composite approach allows the carrier to integrate the beneficial properties of cationic lipids for transfer efficiency while the heterocyclic groups provide reduced cytotoxicity.
2Ease of operation
If nucleic acids are directly administered into the body, then delivery is simplified, but stability in blood deteriorates
Solution Approach 1:
The patent introduces a lipid carrier as an intermediary substance that binds to nucleic acids in the blood. This intermediary complex protects the nucleic acid from degradation while maintaining stability, allowing direct administration without compromising nucleic acid integrity.
3Productivity
If cationic polymer complexes are used to transfer nucleic acids, then transfer capability is improved, but cytotoxicity from polymer increases
Solution Approach 1:
The patent employs lipid-based carriers that are biodegradable and metabolized by the body, replacing persistent polymer structures. The lipid carriers perform their transfer function and are then degraded into harmless components, avoiding the long-term cytotoxicity issues associated with polymer accumulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid particle achieves low cytotoxicity, stable nucleic acid delivery, and rapid release in the cytoplasm, enabling effective function of nucleic acids in target cells while minimizing adverse effects.
Implementation Method 1
the carrier (vector) includes viral carriers and non-viral carriers... cationic carriers that can hold the nucleic acid by electrostatic interaction
Implementation Method 2
an amphoteric liposome obtained by combining cationic lipids with anionic lipids... an amphoteric liposome which consists of an amphoteric-amphiphilic lipid
Data Source
AI summary
The present invention provides a lipid particle which has low cytotoxicity, can stably hold a nucleic acid molecule outside a cell (in blood), and can escape from an endosome and rapidly release the nucleic acid in the cytoplasm; a nucleic acid transfer carrier; a compound for manufacturing a nucleic acid transfer carrier; a method for manufacturing a lipid particle; and a gene transfer method. The lipid particle contains, as constituents, a phospholipid having one or more amino groups and one or more nitrogen-containing heterocyclic groups, a neutral lipid not containing a nitrogen-containing heterocyclic group, a sterol, and a nucleic acid.